One leak good, two leaks bad for Gilead

Late yesterday the non-biotech investment world found out what industry specialists already know: a drug’s chances of success hinge largely on trial design. Data from a Chinese trial of Gilead Sciences’ remdesivir in severe Covid-19, posted by accident by the WHO, suggested that the study was a bust, and had major repercussions for the jittery markets.